Abstract
Objective Genome-wide association studies have identified 1q22 as a susceptibility locus for cerebral small vessel diseases (CSVDs), including non-lobar intracerebral hemorrhage (ICH) and lacunar stroke. In the present study we performed targeted high-depth sequencing of 1q22 in ICH cases and controls to further characterize this locus and prioritize potential causal mechanisms, which remain unknown.
Methods 95,000 base pairs spanning 1q22, including SEMA4A, SLC25A44 and PMF1/PMF1-BGLAP were sequenced in 1,055 spontaneous ICH cases (534 lobar and 521 non-lobar) and 1,078 controls. Firth regression and RIFT analysis were used to analyze common and rare variants, respectively. Chromatin interaction analyses were performed using Hi-C, ChIP-Seq and ChIA-PET databases. Multivariable Mendelian randomization (MVMR) assessed whether alterations in gene-specific expression relative to regionally co-expressed genes at 1q22 could be causally related to ICH risk.
Results Common and rare variant analyses prioritized variants in SEMA4A 5’-UTR and PMF1 intronic regions, overlapping with active promoter and enhancer regions based on ENCODE annotation. Hi-C data analysis determined that 1q22 is spatially organized in a single chromatin loop and that the genes therein belong to the same Topologically Associating Domain. ChIP-Seq and ChIA-PET data analysis highlighted the presence of long-range interactions between the SEMA4A-promoter and PMF1-enhancer regions prioritized by association testing. MVMR analyses demonstrated that PMF1 overexpression could be causally related to non-lobar ICH risk.
Interpretation Altered promoter-enhancer interactions leading to PMF1 overexpression, potentially dysregulating polyamine catabolism, could explain demonstrated associations with non-lobar ICH risk at 1q22, offering a potential new target for prevention of ICH and CSVD.
Competing Interest Statement
J.R. has consulted for Takeda and the National Football League, and receives Sponsored Research Support from the American Heart Association and the National Institutes of Health. C.D.A. has consulted for ApoPharma and has received sponsored research support from Bayer AG and the American Heart Association. B.B.W. is Deputy Editor for the journal Neurology and has received research support from the NIH. M.S.V.E. is an employee of the American Heart Association.
Funding Statement
This work is supported by R01NS103924, R01NS059727, R01NS100178, R01NS105150, U01NS069763 and U19NS115388. Targeted sequencing services were provided by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. Federal Government contract number HHSN268201100037C from the National Heart, Lung, and Blood Institute (RS&G 224). Computations at Wake Forest were performed using the Wake Forest University (WFU) High Performance Computing Facility, a centrally managed computational resource available to WFU researchers including faculty, staff, students, and collaborators (URL https://doi.org/10.57682/g13z-2362).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located on dbGAP (https://www.ncbi.nlm.nih.gov/gap/; Accession ID: phs000416.v2.p1) and on the CDKP portal (https://cd.hugeamp.org/downloads.html). Cis-eQTL data were available on the eQTLGen Consortium portal (https://www.eqtlgen.org).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Additional data supporting these findings are available by the authors, upon reasonable request.
https://www.ncbi.nlm.nih.gov/gap/
